Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ligand Pharmaceuticals (LGND) Gross Margin (2016 - 2025)

Historic Gross Margin for Ligand Pharmaceuticals (LGND) over the last 16 years, with Q3 2025 value amounting to 96.71%.

  • Ligand Pharmaceuticals' Gross Margin rose 14300.0% to 96.71% in Q3 2025 from the same period last year, while for Sep 2025 it was 94.27%, marking a year-over-year increase of 7500.0%. This contributed to the annual value of 93.37% for FY2024, which is 13800.0% up from last year.
  • As of Q3 2025, Ligand Pharmaceuticals' Gross Margin stood at 96.71%, which was up 14300.0% from 93.9% recorded in Q2 2025.
  • Ligand Pharmaceuticals' Gross Margin's 5-year high stood at 96.71% during Q3 2025, with a 5-year trough of 57.1% in Q4 2022.
  • Over the past 5 years, Ligand Pharmaceuticals' median Gross Margin value was 89.4% (recorded in 2023), while the average stood at 85.26%.
  • Per our database at Business Quant, Ligand Pharmaceuticals' Gross Margin tumbled by -216500bps in 2022 and then surged by 370600bps in 2023.
  • Over the past 5 years, Ligand Pharmaceuticals' Gross Margin (Quarter) stood at 78.75% in 2021, then decreased by -27bps to 57.1% in 2022, then soared by 65bps to 94.16% in 2023, then decreased by -1bps to 93.37% in 2024, then grew by 4bps to 96.71% in 2025.
  • Its last three reported values are 96.71% in Q3 2025, 93.9% for Q2 2025, and 89.3% during Q1 2025.